ArticleMolecular medicine (Cambridge, Mass.)2026
Periprostatic adipose tissue-derived extracellular vesicles modulate prostate cancer cell behaviour in vitro according to tumour grade.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SARIFA and Lipid Metabolic Reprogramming in Prostate Cancer: Fundamental Mechanisms, Tumor Microenvironment, and Novel Biomarker Prospects.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPeriprostatic adipose tissue (PPAT) actively interacts with prostate cancer (PCa) cells, partly through the release of extracellular vesicles (EVs). While the cargo of PPAT-derived EVs has been suggested to influence PCa progression, their direct impact on tumour cell behaviour, and importantly, how these effects differ according to patients’ tumour grade, remains unexplored. This study examined whether EVs derived from PPAT of low-risk (ISUP I-II; Low-PPAT EVs) and high-risk (ISUP III-V; High-PPAT EVs) PCa patients differently modulate tumour cell behaviour, immune modulation, and angiogenesis.
methodsEVs were isolated from PPAT from low- and high-risk PCa patients and characterized by nanoparticle tracking analysis, electron microscopy and western blot. EVs (2.5 µg/mL) were tested on androgen-sensitive PCa cell lines (LNCaP, 22Rv1), and their functional effects were assessed on cell proliferation, migration, invasion and apoptosis. Activation of AKT and GSK-3β signalling pathways was also evaluated in PCa cells. Macrophage polarization markers were examined in PMA-differentiated THP-1 cells by measuring the expression of CD80, CD86, CD206, CD163, IL-1β, TNF-α, and MCP-1. Angiogenesis was evaluated through tube formation assays and gene expression analysis in HUVEC cells.
conclusionsThese findings reveal, for the first time, that human PPAT-derived EVs exert risk-dependent effects on PCa progression, emphasizing their key role in PCa progression and emerging as new targetable factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.